Rates of incidental prostate cancer following HoLEP

Can it be predicted preoperatively?

Authors

  • Ahmet Furkan Ozsoy Ankara university school of medicine
  • Çagri Akpinar Ankara University
  • Mehmet Erol Maras Ankara University
  • Muhammed Arif Ibis Ankara University
  • Murat Can Karaburun Ankara Etlik City Hospital
  • Tugba Akkaya Hocagil Ankara University
  • Omer Gulpinar Ankara University
  • Evren Suer Ankara University
  • Mehmet Ilker Gokce Ankara University

DOI:

https://doi.org/10.5489/cuaj.9444

Keywords:

incidental prostat cancer ( iPCa), HoLEP, active surveillance, predictive factors

Abstract

Introduction: This study aimed to identify preoperative predictors of incidental prostate cancer (iPCa) in patients undergoing holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia (BPH) and to evaluate subsequent followup strategies.

Methods: We retrospectively analyzed 571 patients who underwent HoLEP by a single surgeon between 2020 and 2024 and who attended at least one postoperative followup visit at our tertiary center. Demographic features, preoperative clinical parameters, and pathologic findings were recorded. Treatment decisions following the diagnosis of iPCa were also analyzed. To reduce baseline imbalances and ensure analytical rigor, propensity score matching was performed.

Results: The incidence of iPCa was 7.81%. After propensity score matching, elevated preoperative prostate-specfic antigen (PSA) density was significantly associated with the presence of iPCa (odds ratio [OR] 1.095, 95% confidence interval [CI] 1.04–1.16, p=0.01). In a separate analysis, older age (OR 1.11, 95% CI 1.03–1.19, p=0.005), higher total PSA (OR 1.13, 95% CI 1.04–1.22, p= 0.03), and higher PSA density (0.24 vs. 0.04, p<0.001) were identified as clinically significant factors distinguishing the clinically significant prostate cancer group from the clinically insignificant prostate cancer plus benign group.

Conclusions: PSA density was identified as an independent preoperative predictor of incidental prostate cancer following HoLEP, whereas older age, higher total PSA, and elevated PSA density were found to be clinically significant factors associated with clinically significant cases. In older patients with high PSA density, further evaluation for possible prostate cancer may be considered before HoLEP, particularly if the detection of clinically significant disease would alter the decision to proceed with surgery.

Downloads

Download data is not yet available.

Downloads

Published

2026-03-16

How to Cite

Ozsoy, A. F., Akpinar, Çagri, Maras, M. E., Ibis, M. A., Karaburun, M. C., Hocagil, T. A., … Gokce, M. I. (2026). Rates of incidental prostate cancer following HoLEP: Can it be predicted preoperatively?. Canadian Urological Association Journal, 20(7). https://doi.org/10.5489/cuaj.9444

Issue

Vol. 20 No. 7 (2026): CUAJ July

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.